The concept behind the system is to enable both prescription drug manufacturers and pharmaceutical retailers to confirm that appropriate and authentic medications are delivered to patients.
Counterfeit medications are a continuously growing phenomenon. The World
Health Organization predicts that annual counterfeit drug sales will soon
reach
It is estimated that 10 to 25 percent of all drugs sold in developing
countries are either counterfeit or stolen. In countries such as
"It is estimated that 200,000 people die each year from ingesting
counterfeit medications," said,
"Developing products that ensure that appropriate medications are administered to a patient is the mission on Medisafe 1 Technologies," Elhadad added.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad CEO +972-524440000 Jacob.elhadad10@gmail.com
SOURCE Medisafe 1 Technologies Corp.